Denali Therapeutics Statistics
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
18.45+0.25 (+1.37%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Denali Therapeutics by the numbers
Denali Therapeutics has a market capitalization of $2.96 billion based on 160.29M shares outstanding. With trailing EPS of $-1.72, Denali Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 5.0% below its 50-day average and 12.7% below its 200-day average.
Average daily trading volume is 1.68M shares, or about $30.9 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
DNLI valuation vs. peer median
| Metric | DNLI | Peer median | Difference |
|---|---|---|---|
| Market cap | $2.96B | $3.06B | -3% |
| Avg. volume | 1.68M | 2.49M | -33% |
Peer median across 8 companies: ADMA, VCEL, IOVA, RLAY, TARS, BEAM, CRSP, BCRX.
Valuation
- Market cap
- $2.96B
- EPS (TTM)
- $-1.72
- Shares outstanding
- 160.29M
Price and trading
- Previous close
- 18.20
- Open
- 17.95
- Day range
- 17.92 – 18.85
- 52-week range
- 15.34 – 27.30
- 52-week change
- +2.50%
- Beta
- —
- Volume
- 2.63M
- Average volume
- 1.68M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 3, 2026
Additional statistics
- Market Cap
- 2.96B
- Forward Pe
- -8.17
- Eps
- -1.72
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 27.30
- Week52 Low
- 15.34
- Avg Volume
- 1.68M
- Shares Outstanding
- 160.29M
- Ma50
- 19.43
- Ma200
- 21.14
- Earnings Date
- Nov 3, 2026
- Pct From52w High
- -32.42%
- Pct From52w Low
- 20.27%